scholarly journals Pericyte-Based Human Tissue Engineered Vascular Grafts: In Vivo Feasibility Assessment

2010 ◽  
Author(s):  
Wei He ◽  
Alejandro Nieponice ◽  
Lorenzo Soletti ◽  
Yi Hong ◽  
Burhan Gharaibeh ◽  
...  
Keyword(s):  
Vascular Graft ◽  
Small Diameter ◽  
Cellular Delivery ◽  
Self Renewal ◽  
Acute Thrombosis ◽  
Feasibility Assessment ◽  
Adult Mesenchymal Stem Cells ◽  
Cell Source ◽  
Synthetic Grafts

Although autologous vessel grafts are the gold standard for bypass procedures, they are limited by availability in many cases. Current synthetic grafts are not suitable for small-diameter (ID<6mm) vascular applications due to acute thrombosis. While a tissue-engineered vascular graft (TEVG), constructed by incorporating cells within a biodegradable scaffold, seems to be a possible solution to the challenge, its success greatly relies on an appropriate cell source and an efficient cellular delivery and carrier system. Terminally-differentiated vascular cells have poor self-renewal and expansion capabilities, exhibit phenotype switching in culture, and are difficult to harvest in necessary numbers, all of which represent limitations of their use in tissue engineering. Human adult mesenchymal stem cells (MSCs) exhibit multipotentiality and self-renewal capabilities, are more readily available, and therefore could overcome these limitations [1]. Pericytes closely encircle endothelial cells in capillaries. It has been shown that pericytes purified from multiple tissue types displayed multipotentiality, suggesting that they are developmental precursors of MSC [2].

scholarly journals Electrospun poly-ε-caprolactone scaffold modified with catalytic nitric oxide generation and heparin for small-diameter vascular graft

RSC Advances ◽  
2017 ◽  
Vol 7 (30) ◽  
pp. 18775-18784 ◽  
Author(s):  
Jingchen Gao ◽  
Yaping Wang ◽  
Siyuan Chen ◽  
Di Tang ◽  
Li Jiang ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Vascular Surgery ◽  
Vascular Graft ◽  
Vascular Grafts ◽  
Small Diameter ◽  
Peripheral Vascular ◽  
Peripheral Vascular Surgery ◽  
Acute Thrombosis ◽  
Neointimal Proliferation ◽  
Synthetic Grafts

Vascular grafts are significantly needed in peripheral vascular surgery; however, small diameter grafts are not always available, and synthetic grafts perform poorly because of acute thrombosis and neointimal proliferation after implantation.

scholarly journals Decellularised Human Umbilical Artery as a Vascular Graft Elicits Minimal Pro-Inflammatory Host Response Ex Vivo and In Vivo

2021 ◽  
Vol 22 (15) ◽  
pp. 7981
Author(s):  
Alexander Høgsted Ahlmann ◽  
Shu Fang ◽  
Sussi Bagge Mortensen ◽  
Line Weis Andersen ◽  
Pernille Gejl Pedersen ◽  
...  
Keyword(s):  
Vascular Graft ◽  
Umbilical Artery ◽  
Ex Vivo ◽  
White Blood Cells ◽  
Small Diameter ◽  
M1 Macrophages ◽  
Host Immune Responses ◽  
Cytokine Levels ◽  
Anti Inflammatory Cytokine

Small diameter (<6 mm) vessel grafts still pose a challenge for scientists worldwide. Decellularised umbilical artery (dUA) remains promising as small diameter tissue engineered vascular graft (TEVG), yet their immunogenicity remains unknown. Herein, we evaluated the host immune responses, with a focus on the innate part, towards human dUA implantation in mice, and confirmed our findings in an ex vivo allogeneic human setup. Overall, we did not observe any differences in the number of circulating white blood cells nor the number of monocytes among three groups of mice (1) dUA patch; (2) Sham; and (3) Mock throughout the study (day −7 to 28). Likewise, we found no difference in systemic inflammatory and anti-inflammatory cytokine levels between groups. However, a massive local remodelling response with M2 macrophages were observed in the dUA at day 28, whereas M1 macrophages were less frequent. Moreover, human monocytes from allogeneic individuals were differentiated into macrophages and exposed to lyophilised dUA to maximize an eventual M1 response. Yet, dUA did not elicit any immediate M1 response as determined by the absence of CCR7 and CXCL10. Together this suggests that human dUA elicits a minimal pro-inflammatory response further supporting its use as a TEVG in an allogeneic setup.

Development and Biomechanical Characterization of a Novel Bilayer Vascular Graft

2010 ◽  
Author(s):  
Krishna Madhavan ◽  
Walter Bonani ◽  
Craig Lanning ◽  
Wei Tan
Keyword(s):  
Blood Vessel ◽  
Vascular Graft ◽  
Bypass Surgery ◽  
Small Diameter ◽  
Native Artery ◽  
Vessel Lumen ◽  
Unmet Demand ◽  
Tissue Engineered Blood Vessels ◽  
Synthetic Grafts

Vascular grafts are currently used to treat cardiovascular diseases such as arthrosclerosis by bypass surgery and as vascular access in hemodialysis [1]. There are a number of types of grafts including autologous vessels (such saphenous vein), synthetic grafts (such as expanded polytetrafluoroethylene) and tissue engineered blood vessels. Currently synthetic grafts are most commonly used as blood vessel replacements and there are a number of problems associated with them. One main impediment is that these grafts are not suitable for small-diameter (less than 6mm) vessel replacement [1, 2], due to high occlusion rates. The major concern over the other alternatives such as autologous vessels and tissue engineered products is their availability. Thus, new approaches to constructing biomimetic small-diameter blood vessel equivalents, that are immediately available, may address the unmet demand in this area. Therefore, we have designed a novel bilayer vascular construct which is made up of a nanofibrous intimal-equivalent as thromboresistant vessel lumen and a mimetic extracellular matrix (ECM) as medial-equivalent for smooth muscle cells (SMC) from native artery to invade and remodel the ECM.

BIOSPUN VASCULAR GRAFTS: IN VIVO EVALUATION OF A NOVEL SMALL‐DIAMETER BIOACTIVE NANOFIBROUS VASCULAR GRAFT FOR ARTERIAL RECONSTRUCTION

2008 ◽  
Vol 22 (S2) ◽  
pp. 605-605
Author(s):  
Mauricio Antonio Contreras ◽  
Mathew Douglas Phaneuf ◽  
Shengqian Wu ◽  
Martin J. Bide ◽  
Frank W. LoGerfo
Keyword(s):  
Vascular Graft ◽  
Vascular Grafts ◽  
Small Diameter ◽  
Arterial Reconstruction ◽  
In Vivo Evaluation

scholarly journals The in vivo blood compatibility of bio-inspired small diameter vascular graft: effect of submicron longitudinally aligned topography

2013 ◽  
Vol 13 (1) ◽  
Author(s):  
Ruiming Liu ◽  
Yuansen Qin ◽  
Huijin Wang ◽  
Yong Zhao ◽  
Zuojun Hu ◽  
...  
Keyword(s):  
Vascular Graft ◽  
Blood Compatibility ◽  
Small Diameter

A novel small-diameter vascular graft: In vivo behavior of biodegradable three-layered tubular scaffolds

2008 ◽  
Vol 99 (4) ◽  
pp. 1007-1015 ◽  
Author(s):  
Liang Zhang ◽  
Jianye Zhou ◽  
Qingping Lu ◽  
Yingjie Wei ◽  
Shengshou Hu
Keyword(s):  
Vascular Graft ◽  
Small Diameter

The Use of Antithrombotic Therapies in Reducing Synthetic Small-Diameter Vascular Graft Thrombosis

2012 ◽  
Vol 46 (3) ◽  
pp. 212-222 ◽  
Author(s):  
Mark Tatterton ◽  
Stacy-Paul Wilshaw ◽  
Eileen Ingham ◽  
Shervanthi Homer-Vanniasinkam
Keyword(s):  
Vascular Graft ◽  
Animal Experiments ◽  
Small Diameter ◽  
In Vitro Models ◽  
In Vivo Studies ◽  
Synthetic Graft ◽  
Graft Thrombosis ◽  
Medline Search

Background. Thrombosis of synthetic small-diameter bypass grafts remains a major problem. The aim of this article is to review the antithrombotic strategies that have been used in an attempt to reduce graft thrombogenicity. Methods. A PubMed/MEDLINE search was performed using the search terms “vascular graft thrombosis,” “small-diameter graft thrombosis,” “synthetic graft thrombosis” combined with “antithrombotic,” “antiplatelet,” “anticoagulant,” “Dacron,” “PTFE,” and “polyurethane.” Results. The majority of studies on antithrombotic therapies have used either in vitro models or in vivo animal experiments. Many of the therapies used in these settings do show antithrombotic efficacy against synthetic graft materials. There is however, a distinct lack of human in vivo studies to further delineate the performance and limitations of therapies displaying good antithrombotic characteristics. Conclusion. Very few antithrombotic therapies have translated into clinical use. More human in vivo studies are required to assess the efficacy and safety of such therapies.

In vivo biocompatibility and hemocompatibility of a polytetrafluoroethylene small diameter vascular graft modified with sulfonated silk fibroin

2017 ◽  
Vol 213 (1) ◽  
pp. 87-93 ◽  
Author(s):  
Jiaqing Zhang ◽  
Hexi Huang ◽  
Ruihong Ju ◽  
Kuntang Chen ◽  
Shaobin Li ◽  
...  
Keyword(s):  
Silk Fibroin ◽  
Vascular Graft ◽  
Small Diameter

In vivo cell reprogramming to pluripotency: exploring a novel tool for cell replenishment and tissue regeneration

2014 ◽  
Vol 42 (3) ◽  
pp. 711-716 ◽  
Author(s):  
Irene de Lázaro ◽  
Kostas Kostarelos
Keyword(s):  
Pluripotent Stem Cells ◽  
Somatic Cells ◽  
Cell Reprogramming ◽  
Cell Type ◽  
Differentiation Potential ◽  
Self Renewal ◽  
Cell Source ◽  
Induced Pluripotent ◽  
Invasive Techniques

The potential of cell-replacement strategies for the treatment of disorders in which a particular cell type is damaged or degenerated has prompted the search for the perfect cell source. iPSCs (induced pluripotent stem cells) stand out as very advantageous candidates thanks to their self-renewal capacity and differentiation potential, together with the possibility of generating them from autologous somatic cells with minimally invasive techniques. However, their differentiation into the required cell type, precise delivery and successful engraftment and survival in the host are still challenging. We have proposed the transient reprogramming of somatic cells towards a pluripotent state in their in vivo microenvironment as a means to facilitate the regeneration of the tissue. The initial reports of in vivo reprogramming to pluripotency in the literature are reviewed and the potential clinical applications of this strategy are discussed.

Sign in / Sign up

Export Citation Format

Share Document